Congenital bleeding disorder Trials in Berlin, Germany
Conditions / Congenital bleeding disorder / Berlin, Germany
Research into Congenital bleeding disorder spans multiple therapeutic approaches and trial phases.
15 total trials for this combination
Showing top 10 of 15 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03528551 | A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A | COMPLETED | PHASE3 |
| NCT00840086 | Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects | COMPLETED | PHASE3 |
| NCT01631942 | A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects | TERMINATED | PHASE1 |
| NCT01228669 | Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B | COMPLETED | PHASE1 |
| NCT00956345 | Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B | COMPLETED | PHASE1 |
| NCT02490787 | Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects | COMPLETED | PHASE1 |
| NCT01489111 | Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. | COMPLETED | PHASE3 |
| NCT01480180 | Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A | COMPLETED | PHASE3 |
| NCT03075670 | A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B | COMPLETED | PHASE1 |
| NCT00984126 | Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 | COMPLETED | PHASE3 |